Department of General Practice, Erasmus Medical Centre, University Medical Centre Rotterdam, the Netherlands.
Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.
Br J Gen Pract. 2022 Mar 31;72(717):e293-e300. doi: 10.3399/BJGP.2021.0537. Print 2022 Apr.
Long-term opioid treatment in patients with chronic pain is often ineffective and possibly harmful. These patients are often managed by GPs who are calling for a clear overview of effective opioid reduction strategies for primary care.
To evaluate effectiveness of opioid reduction strategies applicable in primary care for patients with chronic pain on long-term opioid treatment.
Systematic review of controlled trials and cohort studies performed in primary care from inception date to 15 January 2021.
Literature search conducted in EMBASE, MEDLINE, Web of Science, Cochrane Central Register of Controlled Trials, CINAHL, Google Scholar, and PsycINFO. Studies evaluating opioid reduction interventions applicable in primary care among adults on long-term opioid treatment for chronic non-cancer pain were included. Risk of bias was assessed using the Cochrane risk-of-bias tool (version 2) (RoB 2) or the Risk of bias in non-randomized studies - of interventions (ROBINS-I) tool. Narrative synthesis was performed because of clinical heterogeneity in study designs and types of interventions.
In total, five randomised controlled trials (RCTs) and five cohort studies were included ( = 1717, range = 35 to = 985) exploring various opioid reduction strategies. Of these, six studies had high/critical RoB, three moderate RoB, and one low RoB. Three cohort studies: investigating a GP-supervised opioid taper (critical ROBINS-I), an integrative pain treatment (moderate ROBINS-I), and group medical visits (critical ROBINS-I) demonstrated significant between-group opioid reduction.
Results carefully point in the direction of a GP supervised tapering and multidisciplinary group therapeutic sessions to reduce long-term opioid treatment. However, because of high risk of bias and small sample sizes, no firm conclusions can be made demonstrating the need for more high-quality research.
慢性疼痛患者的长期阿片类药物治疗通常无效且可能有害。这些患者通常由全科医生管理,他们呼吁对初级保健中有效的阿片类药物减少策略有一个清晰的概述。
评估适用于长期接受阿片类药物治疗的慢性疼痛患者的初级保健中阿片类药物减少策略的有效性。
系统评价在初级保健中进行的对照试验和队列研究,从开始日期到 2021 年 1 月 15 日。
在 EMBASE、MEDLINE、Web of Science、Cochrane 对照试验中心注册库、CINAHL、Google Scholar 和 PsycINFO 中进行文献检索。评估适用于长期接受慢性非癌性疼痛阿片类药物治疗的成年人的阿片类药物减少干预措施的研究。使用 Cochrane 偏倚风险工具(版本 2)(RoB 2)或非随机干预研究的偏倚风险工具(ROBINS-I)评估偏倚风险。由于研究设计和干预类型的临床异质性,进行了叙述性综合。
共纳入 5 项随机对照试验(RCT)和 5 项队列研究(n = 1717,范围 35 至 985),探讨了各种阿片类药物减少策略。其中,6 项研究存在高/关键 ROB,3 项研究为中度 ROB,1 项研究为低 ROB。3 项队列研究:调查了 GP 监督的阿片类药物减量(关键 ROBINS-I)、综合疼痛治疗(中度 ROBINS-I)和小组医疗访问(关键 ROBINS-I),结果显示组间阿片类药物显著减少。
结果谨慎地指出了 GP 监督的减量和多学科小组治疗会议的方向,以减少长期阿片类药物治疗。然而,由于存在高偏倚风险和小样本量,不能得出明确的结论,表明需要进行更多高质量的研究。